Darolutamide Extends Survival in Metastatic Prostate Cancer - NCI

Adding darolutamide (Nubeqa) to ADT and docetaxel improves survival in hormone-sensitive metastatic prostate cancer, results from the ARASENS trial show.

Metastatic Prostate Cancer: Investigators Ponder New Path to

Darolutamide and Survival in Metastatic, Hormone-Sensitive

Metastatic Stage 4 Prostate Cancer Treatments

Nonmetastatic, Castration-Resistant Prostate Cancer and Survival

Darolutamide and Survival in Metastatic, Hormone-Sensitive

Prostate Cancer Treatment Market Size and Share

Hormonal therapies for advanced prostate cancer linked to a higher

Cancers, Free Full-Text

FDA Expands Nubeqa Indications for Prostate Cancer - GoodRx

Nonmetastatic Castration-Resistant Prostate Cancer: Current

ASCO GU 2023: Darolutamide plus ADT Versus ADT in Metastatic

Frontiers Androgen Receptor Signaling in the Development of

ASCO GU 2022: A Randomized, Controlled, Phase 3 Study of

Treatments for Metastatic Hormone-sensitive Prostate Cancer

Abiraterone acetate plus prednisolone with or without enzalutamide